Epeius Biotechnologies Receives Notice of Allowance From USPTO for Nanoparticle Gene Delivery Platform

Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform.

Related Posts

Comments are closed.